サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1357889

世界のアフリベルセプト・バイオシミラー市場：実績と予測 (2018年～2029年) メーカー別、主要地域別、タイプ別、アプリケーション別の詳細データ

Global Aflibercept Biosimilars Market Report, History and Forecast 2018-2029, Breakdown Data by Manufacturers, Key Regions, Types and Application
出版日: | 発行: QYResearch | ページ情報: 英文 119 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
世界のアフリベルセプト・バイオシミラー市場：実績と予測 (2018年～2029年) メーカー別、主要地域別、タイプ別、アプリケーション別の詳細データ
出版日: 2023年10月10日
発行: QYResearch
ページ情報: 英文 119 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、アフリベルセプト・バイオシミラー (Aflibercept Biosimilars) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 アフリベルセプト・バイオシミラー 市場の事業概要

  • アフリベルセプト・バイオシミラー 製品概要
  • アフリベルセプト・バイオシミラー 市場 セグメントタイプ別
    • Intravitreal 注射
    • Intravenous Injection
  • 世界のアフリベルセプト・バイオシミラー 市場規模：タイプ別
    • 世界のアフリベルセプト・バイオシミラー 市場規模の事業概要 タイプ別 (2018-2029)
    • Global Aflibercept Biosimilars Historic Market Size Review by Type (2018-2023)
    • Global Aflibercept Biosimilars Forecasted Market Size by Type (2024-2029)
  • 主要地域別 市場規模 セグメントタイプ別
    • 北米のアフリベルセプト・バイオシミラー 売上 内訳 タイプ別 (2018-2023)
    • Europe Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • Latin America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)

第2章 世界のアフリベルセプト・バイオシミラー市場

  • 世界トップ企業 アフリベルセプト・バイオシミラー 売上 (2018-2023)
  • 世界トップ企業 アフリベルセプト・バイオシミラー 収益 (2018-2023)
  • 世界トップ企業 アフリベルセプト・バイオシミラー 価格 (2018-2023)
  • 世界の企業 アフリベルセプト・バイオシミラーの製造拠点分布, 販売地域,の製品タイプ
  • アフリベルセプト・バイオシミラー 市場 競合の状況と動向
    • アフリベルセプト・バイオシミラーの市場：濃度別 (2018-2023)
    • 世界の5大・10大企業 アフリベルセプト・バイオシミラー 売上高と収益 in 2022
  • 世界の企業 企業タイプ別 (Tier 1, Tier 2 and Tier 3) & (売上高に基づいた in アフリベルセプト・バイオシミラー (2022年時点))
  • 主要企業の参入時期 アフリベルセプト・バイオシミラー 市場
  • 主要企業 アフリベルセプト・バイオシミラー 取扱商品
  • M&A、事業拡大

第3章 アフリベルセプト・バイオシミラー 地域別の現状と展望

  • 世界のアフリベルセプト・バイオシミラー 地域別市場規模および平均年間成長率: 2018 VS 2022 VS 2029
  • 世界のアフリベルセプト・バイオシミラーの市場規模実績：地域別
    • 世界のアフリベルセプト・バイオシミラー 売上：地域別 (2018-2023)
    • 世界のアフリベルセプト・バイオシミラー 売上：地域別 (2018-2023)
    • 世界のアフリベルセプト・バイオシミラー 売上 (数量と金額) 価格と売上総利益 (2018-2023)
  • 世界のアフリベルセプト・バイオシミラーの市場規模予測：地域別
    • 世界のアフリベルセプト・バイオシミラー 売上：地域別 (2024-2029)
    • 世界のアフリベルセプト・バイオシミラー 売上：地域別 (2024-2029)
    • 世界のアフリベルセプト・バイオシミラー 売上（数量・金額）価格、粗利率 (2024-2029)

第4章 世界のアフリベルセプト・バイオシミラー 用途別

  • アフリベルセプト・バイオシミラー 市場セグメント：用途別
    • Wet Macular De世代
    • Metastatic Colorectal Cancer
  • 世界のアフリベルセプト・バイオシミラー 市場規模：用途別
    • 世界のアフリベルセプト・バイオシミラー 市場規模概要：用途別 (2018-2029)
    • 世界のアフリベルセプト・バイオシミラー 市場規模の実績レビュー：用途別 (2018-2023)
    • 世界のアフリベルセプト・バイオシミラーの市場規模予測：用途別 (2024-2029)
  • 主要地域別 市場規模 用途別セグメント
    • 北米のアフリベルセプト・バイオシミラー 売上構成比：用途別 (2018-2023)
    • 欧州のアフリベルセプト・バイオシミラー 売上構成比：用途別 (2018-2023)
    • アジア太平洋地域 アフリベルセプト・バイオシミラー 売上構成比：用途別 (2018-2023)
    • ラテンアメリカのアフリベルセプト・バイオシミラー 売上構成比：用途別 (2018-2023)
    • 中東・アフリカのアフリベルセプト・バイオシミラー 売上構成比：用途別 (2018-2023)

第5章 北米のアフリベルセプト・バイオシミラー 国別

  • 北米のアフリベルセプト・バイオシミラー 市場規模の実績：国別
    • 北米のアフリベルセプト・バイオシミラーの市場規模成長率 (平均年間成長率) 国別: 2018 VS 2022 VS 2029
    • 北米のアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
    • 北米のアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
  • 北米のアフリベルセプト・バイオシミラー 市場規模の予測：国別
    • 北米のアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)
    • 北米のアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)

第6章 欧州のアフリベルセプト・バイオシミラー 国別

  • 欧州のアフリベルセプト・バイオシミラー 市場規模の実績：国別
    • 欧州のアフリベルセプト・バイオシミラーの市場規模成長率 (平均年間成長率) 国別: 2018 VS 2022 VS 2029
    • 欧州のアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
    • 欧州のアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
  • 欧州のアフリベルセプト・バイオシミラー 市場規模の予測：国別
    • 欧州のアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)
    • 欧州のアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)

第7章 アジア太平洋地域 アフリベルセプト・バイオシミラー 地域別

  • アジア太平洋地域 アフリベルセプト・バイオシミラーの市場規模実績：地域別
    • アジア太平洋地域 アフリベルセプト・バイオシミラーの市場規模成長率 (平均年間成長率) 地域別: 2018 VS 2022 VS 2029
    • アジア太平洋地域 アフリベルセプト・バイオシミラー 売上：地域別 (2018-2023)
    • アジア太平洋地域 アフリベルセプト・バイオシミラー 売上：地域別 (2018-2023)
  • アジア太平洋地域 アフリベルセプト・バイオシミラーの市場規模予測：地域別
    • アジア太平洋地域 アフリベルセプト・バイオシミラー 売上：地域別 (2024-2029)
    • アジア太平洋地域 アフリベルセプト・バイオシミラー 売上：地域別 (2024-2029)

第8章 ラテンアメリカのアフリベルセプト・バイオシミラー 国別

  • ラテンアメリカのアフリベルセプト・バイオシミラー 市場規模の実績：国別
    • ラテンアメリカのアフリベルセプト・バイオシミラーの市場規模成長率 (平均年間成長率) 国別: 2018 VS 2022 VS 2029
    • ラテンアメリカのアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
    • ラテンアメリカのアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
  • ラテンアメリカのアフリベルセプト・バイオシミラー 市場規模の予測：国別
    • ラテンアメリカのアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)
    • ラテンアメリカのアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)

第9章 中東・アフリカのアフリベルセプト・バイオシミラー 国別

  • 中東・アフリカのアフリベルセプト・バイオシミラー 市場規模の実績：国別
    • 中東・アフリカのアフリベルセプト・バイオシミラーの市場規模成長率 (平均年間成長率) 国別: 2018 VS 2022 VS 2029
    • 中東・アフリカのアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
    • 中東・アフリカのアフリベルセプト・バイオシミラー 売上：国別 (2018-2023)
  • 中東・アフリカのアフリベルセプト・バイオシミラー 市場規模の予測：国別
    • 中東・アフリカのアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)
    • 中東・アフリカのアフリベルセプト・バイオシミラー 売上：国別 (2024-2029)

第10章 企業プロファイル

  • Bayer
  • Roche
  • Regeneron
  • Sanofi
  • Novartis
  • Sartorius
  • Amgen
  • Samsung Bioepis
  • Mylan
  • Formycon
  • Coherus BioSciences
  • Cadila Pharmaceuticals
  • Hetero
  • Biocon
  • Gene Techno Science
  • Qilu Pharmaceutical

第11章 上流, 機会, 課題, リスクと影響要因の分析

  • アフリベルセプト・バイオシミラー 主要原材料
    • 主要原材料
    • 主要原材料 価格
    • 原材料の主要サプライヤー
  • 製造コスト構造
    • 原材料
    • 人件費
    • 製造コスト
  • アフリベルセプト・バイオシミラー 産業チェーン分析
  • アフリベルセプト・バイオシミラー 市場動向
    • アフリベルセプト・バイオシミラー 業界動向
    • アフリベルセプト・バイオシミラー 市場の促進要因
    • アフリベルセプト・バイオシミラー 市場の課題
    • アフリベルセプト・バイオシミラー 市場の抑制要因

第12章 市場戦略分析、販売代理店

  • 販売チャネル
  • アフリベルセプト・バイオシミラー 卸業者
  • アフリベルセプト・バイオシミラー 下流顧客

第13章 市場調査結果と結論

第14章 付録

図表

List of Tables

  • Table 1. Major Company of Intravitreal Injection
  • Table 2. Major Company of Intravenous Injection
  • Table 3. Global Aflibercept Biosimilars Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
  • Table 4. Global Aflibercept Biosimilars Sales by Type (2018-2023) & (K Units)
  • Table 5. Global Aflibercept Biosimilars Sales Market Share in Volume by Type (2018-2023)
  • Table 6. Global Aflibercept Biosimilars Sales by Type (2018-2023) & (US& Million)
  • Table 7. Global Aflibercept Biosimilars Market Share in Value by Type (2018-2023)
  • Table 8. Global Aflibercept Biosimilars Price by Type (2018-2023) & (USD/Unit)
  • Table 9. Global Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
  • Table 10. Global Aflibercept Biosimilars Sales Market Share in Volume by Type (2024-2029)
  • Table 11. Global Aflibercept Biosimilars Sales by Type (2024-2029) & (US$ Million)
  • Table 12. Global Aflibercept Biosimilars Sales Market Share in Value by Type (2024-2029)
  • Table 13. Global Aflibercept Biosimilars Price by Type (2024-2029) & (USD/Unit)
  • Table 14. North America Aflibercept Biosimilars Sales by Type (2018-2023) & (K Units)
  • Table 15. North America Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 16. Europe Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 17. Europe Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 18. Asia-Pacific Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 19. Asia-Pacific Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 20. Latin America Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 21. Latin America Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 22. Middle East and Africa Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 23. Middle East and Africa Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 24. Global Aflibercept Biosimilars Sales by Company (2018-2023) & (K Units)
  • Table 25. Global Aflibercept Biosimilars Sales Share by Company (2018-2023)
  • Table 26. Global Aflibercept Biosimilars Revenue by Company (2018-2023) & (US$ Million)
  • Table 27. Global Aflibercept Biosimilars Revenue Share by Company (2018-2023)
  • Table 28. Global Market Aflibercept Biosimilars Price by Company (2018-2023) & (USD/Unit)
  • Table 29. Global Aflibercept Biosimilars Top Manufacturers Manufacturing Base Distribution and Sales Area
  • Table 30. Global Aflibercept Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022)
  • Table 32. Date of Key Manufacturers Enter into Aflibercept Biosimilars Market
  • Table 33. Key Manufacturers Aflibercept Biosimilars Product Type
  • Table 34. Mergers & Acquisitions, Expansion Plans
  • Table 35. Global Aflibercept Biosimilars Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
  • Table 36. Global Aflibercept Biosimilars Sales by Region (2018-2023) & (K Units)
  • Table 37. Global Aflibercept Biosimilars Sales Market Share in Volume by Region (2018-2023)
  • Table 38. Global Aflibercept Biosimilars Sales by Region (2018-2023) & (US$ Million)
  • Table 39. Global Aflibercept Biosimilars Sales Market Share in Value by Region (2018-2023)
  • Table 40. Global Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 41. Global Aflibercept Biosimilars Sales by Region (2024-2029) & (K Units)
  • Table 42. Global Aflibercept Biosimilars Sales Market Share in Volume by Region (2024-2029)
  • Table 43. Global Aflibercept Biosimilars Sales by Region (2024-2029) & (US$ Million)
  • Table 44. Global Aflibercept Biosimilars Sales Market Share in Value by Region (2024-2029)
  • Table 45. Global Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2029)
  • Table 46. Global Aflibercept Biosimilars Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 47. Global Aflibercept Biosimilars Sales by Application (2018-2023) & (K Units)
  • Table 48. Global Aflibercept Biosimilars Sales Market Share in Volume by Application (2018-2023)
  • Table 49. Global Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 50. Global Aflibercept Biosimilars Sales Market Share in Value by Application (2018-2023)
  • Table 51. Global Aflibercept Biosimilars Price by Application (2018-2023) & (USD/Unit)
  • Table 52. Global Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
  • Table 53. Global Aflibercept Biosimilars Sales Market Share in Volume by Application (2024-2029)
  • Table 54. Global Aflibercept Biosimilars Sales by Application (2024-2029) & (US$ Million)
  • Table 55. Global Aflibercept Biosimilars Sales Market Share in Value by Application (2024-2029)
  • Table 56. Global Aflibercept Biosimilars Price by Application (2024-2029) & (USD/Unit)
  • Table 57. North America Aflibercept Biosimilars Sales by Application (2018-2023) (K Units)
  • Table 58. North America Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 59. Europe Aflibercept Biosimilars Sales by Application (2018-2023) (K Units)
  • Table 60. Europe Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 61. Asia-Pacific Aflibercept Biosimilars Sales by Application (2018-2023) (K Units)
  • Table 62. Asia-Pacific Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 63. Latin America Aflibercept Biosimilars Sales by Application (2018-2023) (K Units)
  • Table 64. Latin America Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 65. Middle East and Africa Aflibercept Biosimilars Sales by Application (2018-2023) (K Units)
  • Table 66. Middle East and Africa Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 67. North America Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 68. North America Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 69. North America Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 70. North America Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 71. North America Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 72. North America Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 73. North America Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 74. North America Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 75. Europe Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 76. Europe Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 77. Europe Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 78. Europe Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 79. Europe Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 80. Europe Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 81. Europe Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 82. Europe Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 83. Asia-Pacific Aflibercept Biosimilars Sales by Region (2018-2023) & (K Units)
  • Table 84. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Region (2018-2023)
  • Table 85. Asia-Pacific Aflibercept Biosimilars Sales by Region (2018-2023) & (US$ Million)
  • Table 86. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Region (2018-2023)
  • Table 87. Asia-Pacific Aflibercept Biosimilars Sales by Region (2024-2029) & (K Units)
  • Table 88. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Region (2024-2029)
  • Table 89. Asia-Pacific Aflibercept Biosimilars Sales by Region (2024-2029) & (US$ Million)
  • Table 90. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Region (2024-2029)
  • Table 91. Latin America Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 92. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 93. Latin America Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 94. Latin America Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 95. Latin America Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 96. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 97. Latin America Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 98. Latin America Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 99. Middle East and Africa Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 100. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 101. Middle East and Africa Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 102. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 103. Middle East and Africa Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 104. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 105. Middle East and Africa Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 106. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 107. Bayer Company Information
  • Table 108. Bayer Introduction and Business Overview
  • Table 109. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 110. Bayer Aflibercept Biosimilars Product
  • Table 111. Bayer Recent Development
  • Table 112. Roche Company Information
  • Table 113. Roche Introduction and Business Overview
  • Table 114. Roche Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 115. Roche Aflibercept Biosimilars Product
  • Table 116. Roche Recent Development
  • Table 117. Regeneron Company Information
  • Table 118. Regeneron Introduction and Business Overview
  • Table 119. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 120. Regeneron Aflibercept Biosimilars Product
  • Table 121. Regeneron Recent Development
  • Table 122. Sanofi Company Information
  • Table 123. Sanofi Introduction and Business Overview
  • Table 124. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 125. Sanofi Aflibercept Biosimilars Product
  • Table 126. Sanofi Recent Development
  • Table 127. Novartis Company Information
  • Table 128. Novartis Introduction and Business Overview
  • Table 129. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 130. Novartis Aflibercept Biosimilars Product
  • Table 131. Novartis Recent Development
  • Table 132. Sartorius Company Information
  • Table 133. Sartorius Introduction and Business Overview
  • Table 134. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 135. Sartorius Aflibercept Biosimilars Product
  • Table 136. Sartorius Recent Development
  • Table 137. Amgen Company Information
  • Table 138. Amgen Introduction and Business Overview
  • Table 139. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 140. Amgen Aflibercept Biosimilars Product
  • Table 141. Amgen Recent Development
  • Table 142. Samsung Bioepis Company Information
  • Table 143. Samsung Bioepis Introduction and Business Overview
  • Table 144. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 145. Samsung Bioepis Aflibercept Biosimilars Product
  • Table 146. Samsung Bioepis Recent Development
  • Table 147. Mylan Company Information
  • Table 148. Mylan Introduction and Business Overview
  • Table 149. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 150. Mylan Aflibercept Biosimilars Product
  • Table 151. Mylan Recent Development
  • Table 152. Formycon Company Information
  • Table 153. Formycon Introduction and Business Overview
  • Table 154. Formycon Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 155. Formycon Aflibercept Biosimilars Product
  • Table 156. Formycon Recent Development
  • Table 157. Coherus BioSciences Company Information
  • Table 158. Coherus BioSciences Introduction and Business Overview
  • Table 159. Coherus BioSciences Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 160. Coherus BioSciences Aflibercept Biosimilars Product
  • Table 161. Coherus BioSciences Recent Development
  • Table 162. Cadila Pharmaceuticals Company Information
  • Table 163. Cadila Pharmaceuticals Introduction and Business Overview
  • Table 164. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 165. Cadila Pharmaceuticals Aflibercept Biosimilars Product
  • Table 166. Cadila Pharmaceuticals Recent Development
  • Table 167. Hetero Company Information
  • Table 168. Hetero Introduction and Business Overview
  • Table 169. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 170. Hetero Aflibercept Biosimilars Product
  • Table 171. Hetero Recent Development
  • Table 172. Biocon Company Information
  • Table 173. Biocon Introduction and Business Overview
  • Table 174. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 175. Biocon Aflibercept Biosimilars Product
  • Table 176. Biocon Recent Development
  • Table 177. Gene Techno Science Company Information
  • Table 178. Gene Techno Science Introduction and Business Overview
  • Table 179. Gene Techno Science Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 180. Gene Techno Science Aflibercept Biosimilars Product
  • Table 181. Gene Techno Science Recent Development
  • Table 182. Qilu Pharmaceutical Company Information
  • Table 183. Qilu Pharmaceutical Introduction and Business Overview
  • Table 184. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 185. Qilu Pharmaceutical Aflibercept Biosimilars Product
  • Table 186. Qilu Pharmaceutical Recent Development
  • Table 187. Key Raw Materials Lists
  • Table 188. Raw Materials Key Suppliers Lists
  • Table 189. Aflibercept Biosimilars Market Trends
  • Table 190. Aflibercept Biosimilars Market Drivers
  • Table 191. Aflibercept Biosimilars Market Challenges
  • Table 192. Aflibercept Biosimilars Market Restraints
  • Table 193. Aflibercept Biosimilars Distributors List
  • Table 194. Aflibercept Biosimilars Downstream Customers
  • Table 195. Research Programs/Design for This Report
  • Table 196. Key Data Information from Secondary Sources
  • Table 197. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Aflibercept Biosimilars Product Picture
  • Figure 2. Global Aflibercept Biosimilars Market Size, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Aflibercept Biosimilars Market Size Status and Outlook (2018-2029) & (US$ Million)
  • Figure 4. Global Aflibercept Biosimilars Sales Status and Outlook (2018-2029) & (K Units)
  • Figure 5. Product Picture of Intravitreal Injection
  • Figure 6. Global Intravitreal Injection Sales YoY Growth (2018-2029) & (K Units)
  • Figure 7. Product Picture of Intravenous Injection
  • Figure 8. Global Intravenous Injection Sales YoY Growth (2018-2029) & (K Units)
  • Figure 9. Global Aflibercept Biosimilars Sales by Type (2018-2029) & (US$ Million)
  • Figure 10. Global Aflibercept Biosimilars Sales Market Share by Type in 2022 & 2029
  • Figure 11. North America Aflibercept Biosimilars Sales Market Share in Volume by Type in 2022
  • Figure 12. North America Aflibercept Biosimilars Sales Market Share in Value by Type in 2022
  • Figure 13. Europe Aflibercept Biosimilars Sales Market Share in Volume by Type in 2022
  • Figure 14. Europe Aflibercept Biosimilars Sales Market Share in Value by Type in 2022
  • Figure 15. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Type in 2022
  • Figure 16. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Type in 2022
  • Figure 17. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Type in 2022
  • Figure 18. Latin America Aflibercept Biosimilars Sales Market Share in Value by Type in 2022
  • Figure 19. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Volume by Type in 2022
  • Figure 20. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Type in 2022
  • Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Aflibercept Biosimilars Sales in 2022
  • Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Aflibercept Biosimilars Revenue in 2022
  • Figure 23. Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 24. Product Picture of Wet Macular Degeneration
  • Figure 25. Global Wet Macular Degeneration Sales YoY Growth (2018-2029) & (K Units)
  • Figure 26. Product Picture of Metastatic Colorectal Cancer
  • Figure 27. Global Metastatic Colorectal Cancer Sales YoY Growth (2018-2029) & (K Units)
  • Figure 28. Global Aflibercept Biosimilars Sales by Application (2018-2029) & (US$ Million)
  • Figure 29. Global Aflibercept Biosimilars Sales Market Share by Application in 2022 & 2029
  • Figure 30. North America Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 31. North America Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 32. Europe Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 33. Europe Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 34. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 35. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 36. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 37. Latin America Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 38. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 39. Key Raw Materials Price
  • Figure 40. Aflibercept Biosimilars Manufacturing Cost Structure
  • Figure 41. Aflibercept Biosimilars Industrial Chain Analysis
  • Figure 42. Channels of Distribution
  • Figure 43. Distributors Profiles
  • Figure 44. Bottom-up and Top-down Approaches for This Report
  • Figure 45. Data Triangulation
  • Figure 46. Key Executives Interviewed
目次

This research report focuses on the Aflibercept Biosimilars Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Aflibercept Biosimilars Market Overview

  • 1.1 Aflibercept Biosimilars Product Overview
  • 1.2 Aflibercept Biosimilars Market Segment by Type
    • 1.2.1 Intravitreal Injection
    • 1.2.2 Intravenous Injection
  • 1.3 Global Aflibercept Biosimilars Market Size by Type
    • 1.3.1 Global Aflibercept Biosimilars Market Size Overview by Type (2018-2029)
    • 1.3.2 Global Aflibercept Biosimilars Historic Market Size Review by Type (2018-2023)
    • 1.3.3 Global Aflibercept Biosimilars Forecasted Market Size by Type (2024-2029)
  • 1.4 Key Regions Market Size Segment by Type
    • 1.4.1 North America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.2 Europe Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.4 Latin America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)

2 Global Aflibercept Biosimilars Market Competition by Company

  • 2.1 Global Top Players by Aflibercept Biosimilars Sales (2018-2023)
  • 2.2 Global Top Players by Aflibercept Biosimilars Revenue (2018-2023)
  • 2.3 Global Top Players by Aflibercept Biosimilars Price (2018-2023)
  • 2.4 Global Top Manufacturers Aflibercept Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
  • 2.5 Aflibercept Biosimilars Market Competitive Situation and Trends
    • 2.5.1 Aflibercept Biosimilars Market Concentration Rate (2018-2023)
    • 2.5.2 Global 5 and 10 Largest Manufacturers by Aflibercept Biosimilars Sales and Revenue in 2022
  • 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022)
  • 2.7 Date of Key Manufacturers Enter into Aflibercept Biosimilars Market
  • 2.8 Key Manufacturers Aflibercept Biosimilars Product Offered
  • 2.9 Mergers & Acquisitions, Expansion

3 Aflibercept Biosimilars Status and Outlook by Region

  • 3.1 Global Aflibercept Biosimilars Market Size and CAGR by Region: 2018 VS 2022 VS 2029
  • 3.2 Global Aflibercept Biosimilars Historic Market Size by Region
    • 3.2.1 Global Aflibercept Biosimilars Sales in Volume by Region (2018-2023)
    • 3.2.2 Global Aflibercept Biosimilars Sales in Value by Region (2018-2023)
    • 3.2.3 Global Aflibercept Biosimilars Sales (Volume & Value) Price and Gross Margin (2018-2023)
  • 3.3 Global Aflibercept Biosimilars Forecasted Market Size by Region
    • 3.3.1 Global Aflibercept Biosimilars Sales in Volume by Region (2024-2029)
    • 3.3.2 Global Aflibercept Biosimilars Sales in Value by Region (2024-2029)
    • 3.3.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2029)

4 Global Aflibercept Biosimilars by Application

  • 4.1 Aflibercept Biosimilars Market Segment by Application
    • 4.1.1 Wet Macular Degeneration
    • 4.1.2 Metastatic Colorectal Cancer
  • 4.2 Global Aflibercept Biosimilars Market Size by Application
    • 4.2.1 Global Aflibercept Biosimilars Market Size Overview by Application (2018-2029)
    • 4.2.2 Global Aflibercept Biosimilars Historic Market Size Review by Application (2018-2023)
    • 4.2.3 Global Aflibercept Biosimilars Forecasted Market Size by Application (2024-2029)
  • 4.3 Key Regions Market Size Segment by Application
    • 4.3.1 North America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.2 Europe Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.4 Latin America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)

5 North America Aflibercept Biosimilars by Country

  • 5.1 North America Aflibercept Biosimilars Historic Market Size by Country
    • 5.1.1 North America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 5.1.2 North America Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 5.1.3 North America Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 5.2 North America Aflibercept Biosimilars Forecasted Market Size by Country
    • 5.2.1 North America Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 5.2.2 North America Aflibercept Biosimilars Sales in Value by Country (2024-2029)

6 Europe Aflibercept Biosimilars by Country

  • 6.1 Europe Aflibercept Biosimilars Historic Market Size by Country
    • 6.1.1 Europe Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 6.1.2 Europe Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 6.1.3 Europe Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 6.2 Europe Aflibercept Biosimilars Forecasted Market Size by Country
    • 6.2.1 Europe Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 6.2.2 Europe Aflibercept Biosimilars Sales in Value by Country (2024-2029)

7 Asia-Pacific Aflibercept Biosimilars by Region

  • 7.1 Asia-Pacific Aflibercept Biosimilars Historic Market Size by Region
    • 7.1.1 Asia-Pacific Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
    • 7.1.2 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2018-2023)
    • 7.1.3 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2018-2023)
  • 7.2 Asia-Pacific Aflibercept Biosimilars Forecasted Market Size by Region
    • 7.2.1 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2024-2029)
    • 7.2.2 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2024-2029)

8 Latin America Aflibercept Biosimilars by Country

  • 8.1 Latin America Aflibercept Biosimilars Historic Market Size by Country
    • 8.1.1 Latin America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 8.1.2 Latin America Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 8.1.3 Latin America Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 8.2 Latin America Aflibercept Biosimilars Forecasted Market Size by Country
    • 8.2.1 Latin America Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 8.2.2 Latin America Aflibercept Biosimilars Sales in Value by Country (2024-2029)

9 Middle East and Africa Aflibercept Biosimilars by Country

  • 9.1 Middle East and Africa Aflibercept Biosimilars Historic Market Size by Country
    • 9.1.1 Middle East and Africa Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 9.1.2 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 9.1.3 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 9.2 Middle East and Africa Aflibercept Biosimilars Forecasted Market Size by Country
    • 9.2.1 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 9.2.2 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2024-2029)

10 Company Profiles

  • 10.1 Bayer
    • 10.1.1 Bayer Company Information
    • 10.1.2 Bayer Introduction and Business Overview
    • 10.1.3 Bayer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.1.4 Bayer Aflibercept Biosimilars Products Offered
    • 10.1.5 Bayer Recent Development
  • 10.2 Roche
    • 10.2.1 Roche Company Information
    • 10.2.2 Roche Introduction and Business Overview
    • 10.2.3 Roche Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.2.4 Roche Aflibercept Biosimilars Products Offered
    • 10.2.5 Roche Recent Development
  • 10.3 Regeneron
    • 10.3.1 Regeneron Company Information
    • 10.3.2 Regeneron Introduction and Business Overview
    • 10.3.3 Regeneron Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.3.4 Regeneron Aflibercept Biosimilars Products Offered
    • 10.3.5 Regeneron Recent Development
  • 10.4 Sanofi
    • 10.4.1 Sanofi Company Information
    • 10.4.2 Sanofi Introduction and Business Overview
    • 10.4.3 Sanofi Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.4.4 Sanofi Aflibercept Biosimilars Products Offered
    • 10.4.5 Sanofi Recent Development
  • 10.5 Novartis
    • 10.5.1 Novartis Company Information
    • 10.5.2 Novartis Introduction and Business Overview
    • 10.5.3 Novartis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.5.4 Novartis Aflibercept Biosimilars Products Offered
    • 10.5.5 Novartis Recent Development
  • 10.6 Sartorius
    • 10.6.1 Sartorius Company Information
    • 10.6.2 Sartorius Introduction and Business Overview
    • 10.6.3 Sartorius Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.6.4 Sartorius Aflibercept Biosimilars Products Offered
    • 10.6.5 Sartorius Recent Development
  • 10.7 Amgen
    • 10.7.1 Amgen Company Information
    • 10.7.2 Amgen Introduction and Business Overview
    • 10.7.3 Amgen Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.7.4 Amgen Aflibercept Biosimilars Products Offered
    • 10.7.5 Amgen Recent Development
  • 10.8 Samsung Bioepis
    • 10.8.1 Samsung Bioepis Company Information
    • 10.8.2 Samsung Bioepis Introduction and Business Overview
    • 10.8.3 Samsung Bioepis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.8.4 Samsung Bioepis Aflibercept Biosimilars Products Offered
    • 10.8.5 Samsung Bioepis Recent Development
  • 10.9 Mylan
    • 10.9.1 Mylan Company Information
    • 10.9.2 Mylan Introduction and Business Overview
    • 10.9.3 Mylan Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.9.4 Mylan Aflibercept Biosimilars Products Offered
    • 10.9.5 Mylan Recent Development
  • 10.10 Formycon
    • 10.10.1 Formycon Company Information
    • 10.10.2 Formycon Introduction and Business Overview
    • 10.10.3 Formycon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.10.4 Formycon Aflibercept Biosimilars Products Offered
    • 10.10.5 Formycon Recent Development
  • 10.11 Coherus BioSciences
    • 10.11.1 Coherus BioSciences Company Information
    • 10.11.2 Coherus BioSciences Introduction and Business Overview
    • 10.11.3 Coherus BioSciences Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.11.4 Coherus BioSciences Aflibercept Biosimilars Products Offered
    • 10.11.5 Coherus BioSciences Recent Development
  • 10.12 Cadila Pharmaceuticals
    • 10.12.1 Cadila Pharmaceuticals Company Information
    • 10.12.2 Cadila Pharmaceuticals Introduction and Business Overview
    • 10.12.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.12.4 Cadila Pharmaceuticals Aflibercept Biosimilars Products Offered
    • 10.12.5 Cadila Pharmaceuticals Recent Development
  • 10.13 Hetero
    • 10.13.1 Hetero Company Information
    • 10.13.2 Hetero Introduction and Business Overview
    • 10.13.3 Hetero Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.13.4 Hetero Aflibercept Biosimilars Products Offered
    • 10.13.5 Hetero Recent Development
  • 10.14 Biocon
    • 10.14.1 Biocon Company Information
    • 10.14.2 Biocon Introduction and Business Overview
    • 10.14.3 Biocon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.14.4 Biocon Aflibercept Biosimilars Products Offered
    • 10.14.5 Biocon Recent Development
  • 10.15 Gene Techno Science
    • 10.15.1 Gene Techno Science Company Information
    • 10.15.2 Gene Techno Science Introduction and Business Overview
    • 10.15.3 Gene Techno Science Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.15.4 Gene Techno Science Aflibercept Biosimilars Products Offered
    • 10.15.5 Gene Techno Science Recent Development
  • 10.16 Qilu Pharmaceutical
    • 10.16.1 Qilu Pharmaceutical Company Information
    • 10.16.2 Qilu Pharmaceutical Introduction and Business Overview
    • 10.16.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.16.4 Qilu Pharmaceutical Aflibercept Biosimilars Products Offered
    • 10.16.5 Qilu Pharmaceutical Recent Development

11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis

  • 11.1 Aflibercept Biosimilars Key Raw Materials
    • 11.1.1 Key Raw Materials
    • 11.1.2 Key Raw Materials Price
    • 11.1.3 Raw Materials Key Suppliers
  • 11.2 Manufacturing Cost Structure
    • 11.2.1 Raw Materials
    • 11.2.2 Labor Cost
    • 11.2.3 Manufacturing Expenses
  • 11.3 Aflibercept Biosimilars Industrial Chain Analysis
  • 11.4 Aflibercept Biosimilars Market Dynamics
    • 11.4.1 Aflibercept Biosimilars Industry Trends
    • 11.4.2 Aflibercept Biosimilars Market Drivers
    • 11.4.3 Aflibercept Biosimilars Market Challenges
    • 11.4.4 Aflibercept Biosimilars Market Restraints

12 Market Strategy Analysis, Distributors

  • 12.1 Sales Channel
  • 12.2 Aflibercept Biosimilars Distributors
  • 12.3 Aflibercept Biosimilars Downstream Customers

13 Research Findings and Conclusion

14 Appendix

  • 14.1 Research Methodology
    • 14.1.1 Methodology/Research Approach
    • 14.1.2 Data Source
  • 14.2 Author Details
  • 14.3 Disclaimer